Home > Healthcare > Medical Devices > Diagnostic Devices > Acute Lymphoblastic Leukemia Therapeutics Market

Acute Lymphoblastic Leukemia Therapeutics Market Trends

Report ID: GMI8368
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Acute Lymphoblastic Leukemia Therapeutics Market Trends

ALL is the most common type of childhood cancer, and its incidence has been rising globally over the past few decades. While it is more prevalent in children, ALL can also occur in adults, albeit less frequently. For instance, according to an article published in National Health Institutes, the estimated annual incidence of ALL is 1 to 5 cases/100,000 population, and more than two-thirds of cases of ALL are of the B-cell phenotype globally. Italy, the USA, Switzerland, and Costa Rica are the countries with the highest ALL incidence.
Advancements in research and development have propelled the field forward, with significant progress in genomics, molecular biology, immunology, and drug discovery. These advancements have led to the identification of novel therapeutic targets, the development of targeted therapies and immunotherapies, and the initiation of clinical trials evaluating promising new treatments.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global acute lymphoblastic leukemia therapeutics industry size was USD 3 billion in 2023 and is predicted to grow at 6.8% CAGR up to 2032 driven by the rising prevalence of acute lymphoblastic leukemia and the increasing number of product approvals.

The chemotherapy segment is anticipated to record 7.6% CAGR from 2024 to 2032 as it has been the primary treatment approach for several decades.

North America acute lymphoblastic leukemia therapeutics industry size is projected to reach USD 2 billion by 2032 as the region boasts a highly developed healthcare infrastructure with advanced medical facilities, specialized cancer centers, and state-of-the-art equipment.

Bristol Myer Squibb Company, Celegene Corporation, Eisai Co Ltd., Erytech Pharma, F. Hoffmann-La Roche Ltd., Genmab A/S, GlaxoSmithKline PLC, Novartis AG, Pfizer, Inc., and Sanofi S.A.